Glycopyrronium, Indacaterol, and Mometasone combination is a novel inhaled medication approved for the management of chronic obstructive pulmonary disease (COPD) and asthma. This fixed-dose combination offers a triple therapy approach, providing bronchodilation and anti-inflammatory effects. Glycopyrronium, an anticholinergic; Indacaterol, a long-acting β2-agonist (LABA); and Mometasone, a corticosteroid, work synergistically to relieve airway obstruction and inflammation. The combination was approved by the European Medicines Agency (EMA) in 2020 and has been studied in various clinical trials demonstrating efficacy in reducing exacerbations and improving lung function.

FDA-approved uses of this combination include:

• Management of Chronic Obstructive Pulmonary Disease (COPD)
• Treatment of Asthma (in patients where monotherapy is insufficient)
• Reducing exacerbation rates in patients with COPD or asthma

The combination is administered via inhalation using a dry powder inhaler or pressurised metered-dose inhaler. The standard dosage is usually one inhalation daily, but specific doses may vary based on the severity of the condition and patient response. It is essential to follow the prescribing healthcare provider's instructions for optimal results.

Serious Side Effects

• Irregular heartbeats
• Severe allergic reactions (rash, itching, swelling)
• Chest pain or discomfort
• Vision changes (e.g., blurred vision, eye pain)
• Difficulty urinating

Common Side Effects

• Dry mouth
• Cough
• Headache
• Sore throat
• Nausea
• Hoarseness

• Not suitable for individuals with severe hypersensitivity to any of the active ingredients.
• May interact adversely with other bronchodilators or corticosteroids.
• Increased risk of cardiovascular complications in patients with underlying heart conditions.
• Avoid use during acute asthma or COPD exacerbations requiring emergency intervention.
• Should not be used as the primary treatment for asthma relief.

Before using this combination therapy, patients should inform their healthcare provider of their complete medical history, especially if they have heart disease, hypertension, glaucoma, urinary retention, or osteoporosis. Regular monitoring of lung function and bone density is advisable during prolonged use. Patients should be cautious about potential side effects and consult their physician if symptoms worsen or new symptoms emerge.

This combination therapy is most effective when used regularly, as prescribed. It is not intended for the relief of acute symptoms, and patients should always carry a rescue inhaler for emergency situations. Rinsing the mouth after inhalation is advisable to prevent oral thrush. Store the inhaler in a cool, dry place and avoid exposure to extreme temperatures.

1. https://pubmed.ncbi.nlm.nih.gov/33871819/
2. https://www.ncbi.nlm.nih.gov/books/NBK568878/
3. https://www.sciencedirect.com/science/article/pii/S1094553920301681
4. https://adisinsight.springer.com/drugs/800042720 

This content is intended for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.